Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPt-Ca for Pediatric Brain Stem Glioma and Recurrent CNS Tumors
NCT03250520Phase 1Completed
- Sponsor
- Hospital Infantil de México Federico Gómez
- Start
- Sep 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of nedaplatin + capecitabine in brainstem glioma and central nervous system tumor (2 arms), sponsored by Hospital Infantil de México Federico Gómez. Primary endpoints: Change in the quality of life using the PedsQL Cancer Module at 24 months and Change in tumor size at 24 months. Started Sep 2017; status: completed.
02
Drugs
nedaplatin + capecitabine
03
Conditions
brainstem gliomacentral nervous system tumor
Beyond the preview
Go deeper on NCT03250520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03250520.